No Data
No Data
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright analyst Mitchell Kapoor maintains $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4
Analysts Are Bullish on These Healthcare Stocks: Instil Bio (TIL), Lexeo Therapeutics, Inc. (LXEO)
Express News | Lexeo Therapeutics Inc : Leerink Partners Raises Target Price to $22 From $19
Lexeo Therapeutics (LXEO.US) achieved positive results in the clinical trial of gene therapy LX2006.
On July 16th, Lexeo Therapeutics (LXEO.US) announced positive mid-stage data for its gene therapy LX2006, which is being developed to treat Friedreich's ataxia (FA) cardiomyopathy.
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.
Lexeo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 75.84% Chardan Capital $23 → $23 Maintains Buy 06/13/2024 114.07% Baird → $28 Initiates
No Data